Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

i

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-nCoV/index.html

Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States

Filetype[PDF-379.79 KB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Corporate Authors:
      National Center for Immunization and Respiratory Diseases (U.S.)
    • Content Notes:
      Background -- Age groups approved or authorized to receive COVID-19 vaccine by vaccine product -- COVID-19 vaccine administration -- Interchangeability of COVID-19 vaccine products -- People vaccinated for COVID-19 outside the United States -- People vaccinated for COVID-19 as part of a clinical trial in the United States -- Coadministration of COVID-19 vaccines with other vaccines -- COVID-19 vaccination and SARS-CoV-2 infection -- Antiviral therapy and COVID-19 vaccination -- Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks -- Considerations for use of an additional dose of COVID-19 vaccine following a primary vaccine series -- Considerations for use of an additional mRNA COVID-19 vaccine dose after an initial 2-dose COVID-19 mRNA vaccine series for immunocompromised people -- Considerations for vaccination of people with certain underlying medical conditions -- Considerations for use of the Janssen COVID-19 vaccine in certain populations -- Considerations involving pregnancy, lactation, and fertility -- Vaccination of children and adolescents -- Patient counseling -- Contraindications and precautions -- Reporting of vaccine adverse events -- Laboratory testing -- Appendix A. Vaccine administration errors and deviations -- Appendix B: Triage of people with a history of allergies or allergic reactions -- Appendix C: Ingredients included in COVID-19 vaccines -- Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following COVID-19 vaccination -- References -- Previous Updates.
    • Subjects:
    • Document Type:
      Webpage
    • Place as Subject:
      United States
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    Supporting Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov